{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:12:13Z","timestamp":1789229533155,"version":"build-2803163510"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Postmenopausal individuals with type 2 diabetes are susceptible to fractures due to the interaction of elevated blood glucose levels and a deficiency of the hormone estrogen. Despite continued concerns of fracture risks associated with sodium-glucose cotransporter 2 inhibitors (SGLT2i), existing evidence in this high-risk population is lacking.<\/jats:p><\/jats:sec>Objective<\/jats:title>To assess the risk of fractures associated with SGLT2i vs incretin-based drugs of dipeptidyl-peptidase 4 inhibitors (DPP4i) and glucagon-like peptide 1 receptor agonists (GLP1RA), separately, in postmenopausal individuals with type 2 diabetes.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This active-comparator, new-user cohort study used nationwide claims data of Korea and took place from January 1, 2013, to December 31, 2020. Postmenopausal individuals (aged \u226545 years) with type 2 diabetes were included.<\/jats:p><\/jats:sec>Exposures<\/jats:title>New users of SGLT2i or comparator drugs.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was overall fractures, comprising vertebral, hip, humerus, and distal radius fractures. Patients were followed up from the day after drug initiation until the earliest of outcome occurrence, drug discontinuation (90-day grace period) or switch, death, or end of the study period. After propensity score fine stratification, hazard ratios (HRs) with 95% CIs were estimated using weighted Cox models.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 37\u202f530 (mean [SD] age, 60.6 [9.7] years) and 332\u202f004 (mean [SD] age, 60.6 [9.9] years) new users of SGLT2i and DPP4i, respectively, a lower rate of incident overall fractures was presented with SGLT2i vs DPP4i (weighted HR, 0.78; 95% CI, 0.72-0.84). Among 111\u202f835 (mean [SD] age, 61.4 [9.8] years) and 8177 (mean [SD] age, 61.1 [10.3] years) new users of SGLT2i and GLP1RA, respectively, no association with an increased risk of overall fractures was presented with SGLT2i vs GLP1RA (weighted HR, 0.92; 95% CI, 0.68-1.24). Results from several subgroup and sensitivity analyses presented consistent results from main analysis.<\/jats:p><\/jats:sec>Conclusions and relevance<\/jats:title>This population-based cohort study suggests that SGLT2i was not associated with an increased rate of incident fractures compared with DPP4i and GLP1RA, separately, among postmenopausal individuals with type 2 diabetes.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.35797","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T15:00:59Z","timestamp":1695740459000},"page":"e2335797","source":"Crossref","is-referenced-by-count":24,"title":["Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes"],"prefix":"10.1001","volume":"6","author":[{"given":"Hwa Yeon","family":"Ko","sequence":"first","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungho","family":"Bea","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Eol","family":"Jeong","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"},{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohee","family":"Park","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"},{"name":"Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Min","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea"},{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hye","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"},{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea"},{"name":"Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"zoi231027r1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jsbmb.2013.09.008","article-title":"Prevention and treatment of postmenopausal osteoporosis.","volume":"142","author":"Tella","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"zoi231027r2","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00198-020-05771-9","article-title":"The diabetes-fracture association in women with type 1 and type 2 diabetes is partially mediated by falls: a 15-year longitudinal study.","volume":"32","author":"Thong","year":"2021","journal-title":"Osteoporos Int"},{"issue":"5","key":"zoi231027r3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1530\/EJE-20-1155","article-title":"The doubled burden of diabetic bone disease: hip fracture and post-hip fracture mortality.","volume":"184","author":"Behanova","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"zoi231027r4","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41574-021-00555-5","article-title":"Update on the pathogenesis and treatment of skeletal fragility in type 2 diabetes mellitus.","volume":"17","author":"Khosla","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"zoi231027r5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nrendo.2016.153","article-title":"Mechanisms of diabetes mellitus-induced bone fragility.","volume":"13","author":"Napoli","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"22","key":"zoi231027r6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi231027r7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi231027r8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi231027r9","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes.","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"zoi231027r10","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2023.","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"zoi231027r11","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3389\/fphar.2018.01517","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on bone metabolism and fracture risk.","volume":"9","author":"Ye","year":"2019","journal-title":"Front Pharmacol"},{"issue":"1","key":"zoi231027r12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12933-022-01476-x","article-title":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.","volume":"21","author":"Kaze","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"zoi231027r13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.diabet.2019.01.010","article-title":"Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials.","volume":"45","author":"Cheng","year":"2019","journal-title":"Diabetes Metab"},{"issue":"12","key":"zoi231027r14","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/dom.12742","article-title":"Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.","volume":"18","author":"Tang","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"zoi231027r15","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.2337\/dc19-0849","article-title":"Sodium-glucose cotransporter 2 inhibitors and the risk of fractures among patients with type 2 diabetes.","volume":"42","author":"Abrahami","year":"2019","journal-title":"Diabetes Care"},{"key":"zoi231027r16","doi-asserted-by":"publisher","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"zoi231027r17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7326\/M18-0567","article-title":"Fracture risk after initiation of use of canagliflozin: a cohort study.","volume":"170","author":"Fralick","year":"2019","journal-title":"Ann Intern Med"},{"issue":"10","key":"zoi231027r18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.30762","article-title":"Association of Sodium-glucose cotransporter-2 inhibitors with fracture risk in older adults with type 2 diabetes.","volume":"4","author":"Zhuo","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi231027r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109993","article-title":"Use of sodium-glucose co-transporter 2 inhibitors, changes in body mass index and risk of fracture: a population-based cohort study.","volume":"190","author":"van Dalem","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"zoi231027r20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"zoi231027r21","doi-asserted-by":"publisher","first-page":"1026.e1","DOI":"10.1016\/j.jhsa.2021.03.001","article-title":"Validation of an operational definition to identify distal radius fractures in a national health insurance database.","volume":"46","author":"Lee","year":"2021","journal-title":"J Hand Surg Am"},{"issue":"2","key":"zoi231027r22","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.spinee.2019.09.025","article-title":"Incidence and mortality of subsequent vertebral fractures: analysis of claims data of the Korea National Health Insurance Service from 2007 to 2016.","volume":"20","author":"Park","year":"2020","journal-title":"Spine J"},{"issue":"7","key":"zoi231027r23","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e48","article-title":"Incidence and seasonal variation of distal radius fractures in Korea: a population-based study.","volume":"33","author":"Jo","year":"2018","journal-title":"J Korean Med Sci"},{"issue":"1","key":"zoi231027r24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12891-019-2515-2","article-title":"Surgical trends in elderly patients with proximal humeral fractures in South Korea: a population-based study.","volume":"20","author":"Jo","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"zoi231027r25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.11005\/jbm.2019.26.2.105","article-title":"Incidence of osteoporotic refractures following proximal humerus fractures in adults aged 50 years and older in Korea.","volume":"26","author":"Jung","year":"2019","journal-title":"J Bone Metab"},{"issue":"2","key":"zoi231027r26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00198-012-2016-8","article-title":"Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry.","volume":"24","author":"Lee","year":"2013","journal-title":"Osteoporos Int"},{"issue":"32","key":"zoi231027r27","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2022.37.e249","article-title":"Operational definition identifying osteoporotic vertebral fractures in the claims database.","volume":"37","author":"Yu","year":"2022","journal-title":"J Korean Med Sci"},{"key":"zoi231027r28","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"25","key":"zoi231027r29","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","article-title":"Empagliflozin and the risk of heart failure hospitalization in routine clinical care.","volume":"139","author":"Patorno","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"zoi231027r30","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1056\/NEJMc1600827","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"374","author":"Zinman","year":"2016","journal-title":"N Engl J Med"},{"key":"zoi231027r31","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.825417","article-title":"Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 177 randomized controlled trials with a median follow-up of 26 weeks.","volume":"13","author":"Chai","year":"2022","journal-title":"Front Pharmacol"},{"issue":"10","key":"zoi231027r32","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-019-04968-x","article-title":"Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.","volume":"30","author":"Hidayat","year":"2019","journal-title":"Osteoporos Int"},{"key":"zoi231027r33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.bone.2015.07.025","article-title":"SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA\/2J male mice.","volume":"82","author":"Thrailkill","year":"2016","journal-title":"Bone"},{"issue":"1","key":"zoi231027r34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin.","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"zoi231027r35","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1210\/js.2019-00160","article-title":"Advanced glycation end products (AGEs), receptor for AGEs, diabetes, and bone: review of the literature.","volume":"3","author":"Asadipooya","year":"2019","journal-title":"J Endocr Soc"},{"issue":"6","key":"zoi231027r36","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","article-title":"Advanced glycation end products: sparking the development of diabetic vascular injury.","volume":"114","author":"Goldin","year":"2006","journal-title":"Circulation"},{"issue":"2","key":"zoi231027r37","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S2213-8587(15)00283-1","article-title":"Type 2 diabetes and the skeleton: new insights into sweet bones.","volume":"4","author":"Shanbhogue","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"zoi231027r38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S2213-8587(21)00347-8","article-title":"Bone fragility in diabetes: novel concepts and clinical implications.","volume":"10","author":"Hofbauer","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"zoi231027r39","doi-asserted-by":"publisher","first-page":"22090","DOI":"10.1038\/s41598-020-78993-w","article-title":"Pentosidine and carboxymethyl-lysine associate differently with prevalent osteoporotic vertebral fracture and various bone markers.","volume":"10","author":"Nakano","year":"2020","journal-title":"Sci Rep"},{"key":"zoi231027r40","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol"},{"issue":"9","key":"zoi231027r41","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1055\/s-00000025","article-title":"Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis.","volume":"47","author":"Ojima","year":"2015","journal-title":"Horm Metab Res"},{"issue":"1","key":"zoi231027r42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.maturitas.2010.04.015","article-title":"Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates.","volume":"67","author":"Phipps","year":"2010","journal-title":"Maturitas"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2809929\/ko_2023_oi_231027_1695236122.20582.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T15:01:02Z","timestamp":1695740462000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2809929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.35797","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,26]]}}}